Cowen reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note issued to investors on Thursday morning, AnalystRatings.com reports.
“On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated.”,” the firm’s analyst commented.
KRYS has been the subject of several other reports. Chardan Capital increased their target price on Krystal Biotech from $57.50 to $75.00 and gave the company a buy rating in a research report on Monday, June 24th. Guggenheim increased their target price on Krystal Biotech from $48.00 to $73.00 and gave the company a buy rating in a research report on Tuesday, June 25th. ValuEngine downgraded Krystal Biotech from a strong-buy rating to a buy rating in a research report on Friday, August 2nd. Zacks Investment Research cut Krystal Biotech from a buy rating to a hold rating in a research note on Wednesday, July 24th. Finally, William Blair reissued a buy rating on shares of Krystal Biotech in a research note on Monday, June 24th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $59.20.
Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, analysts predict that Krystal Biotech will post -1.47 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Laurion Capital Management LP grew its stake in Krystal Biotech by 117.7% during the first quarter. Laurion Capital Management LP now owns 37,383 shares of the company’s stock worth $1,230,000 after purchasing an additional 20,213 shares during the period. Alps Advisors Inc. grew its stake in Krystal Biotech by 4.5% during the first quarter. Alps Advisors Inc. now owns 34,851 shares of the company’s stock worth $1,147,000 after purchasing an additional 1,507 shares during the period. MYDA Advisors LLC acquired a new stake in Krystal Biotech during the first quarter worth approximately $296,000. BlackRock Inc. grew its stake in Krystal Biotech by 41.0% during the fourth quarter. BlackRock Inc. now owns 19,157 shares of the company’s stock worth $398,000 after purchasing an additional 5,568 shares during the period. Finally, Geode Capital Management LLC grew its stake in Krystal Biotech by 66.2% during the fourth quarter. Geode Capital Management LLC now owns 60,603 shares of the company’s stock worth $1,259,000 after purchasing an additional 24,137 shares during the period. 38.59% of the stock is owned by institutional investors and hedge funds.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: What is a CD ladder?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.